Eton Pharmaceuticals to join Russell 2000 and 3000 indexes

DEER PARK, Ill. - Eton Pharmaceuticals, Inc (Nasdaq:ETON) will be added to the Russell 3000 and Russell 2000 Indexes effective after market close today, according to a company press release.

The rare disease-focused pharmaceutical company’s inclusion comes as part of the 2025 Russell Indexes annual reconstitution process.

"Eton’s addition to the Russell 2000 and Russell 3000 Indexes is a significant milestone," said Sean Brynjelsen, CEO of Eton Pharmaceuticals, in the statement.

The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

Eton Pharmaceuticals currently markets eight commercial rare disease products including KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The company also has five additional product candidates in late-stage development.

The Russell 3000 Index measures the performance of the largest 3,000 U.S. companies, while the Russell 2000 Index specifically tracks the small-cap segment of the U.S. equity market.

Inclusion in these indexes can potentially increase a company’s visibility among institutional investors who use these benchmarks to guide investment decisions.

In other recent news, Eton Pharmaceuticals reported impressive first-quarter 2025 earnings, with revenue reaching $17.3 million, a 117% increase compared to the previous year. This growth was primarily driven by strong product sales and licensing revenue, with product sales contributing $14 million. The company also received FDA approval for KHINDIVI, a hydrocortisone oral solution for pediatric patients with adrenocortical insufficiency, marking the first FDA-approved oral solution of its kind. Analysts at H.C. Wainwright raised the price target for Eton Pharmaceuticals to $35, maintaining a Buy rating, reflecting confidence in the company’s commercial execution. The firm projects Eton’s revenue to reach $74 million in 2025, a significant increase from $39 million in 2024. Eton Pharmaceuticals is also preparing to launch KHINDIVI through Anovo, a specialty pharmacy, starting the week of June 2. The company’s CEO, Sean Brynjelsen, expressed readiness to commercialize the new treatment, complementing Eton’s existing portfolio. Additionally, the Eton Cares Program will support patients with prescription fulfillment, educational support, and financial assistance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.